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OBJECTIVES: This study aimed to investigate the clinical correlation between angiographic coronary
atherosclerosis and N-terminal pro-B-type natriuretic peptide along with other known correlated factors.
METHODS: In total, 153 patients with a diagnostic hypothesis of stable angina, unstable angina or acute
myocardial infarction were classified as group A (patients with angiographically normal coronary arteries) or
group B (patients with angiographic coronary atherosclerosis). The two groups were analyzed with respect to
the following factors: gender, age, body mass index, abdominal circumference, smoking, diabetes mellitus,
arterial hypertension, early family history of atherosclerosis, statin use, the presence of metabolic syndrome,
clinical presentation and biochemical factors, including cholesterol, creatinine and fibrinogen plasma
concentrations, monocyte counts and N-terminal pro-B-type natriuretic peptide.
RESULTS: Univariate analyses comparing the two groups revealed that group B patients more frequently had
diabetes, used statins and had systolic dysfunction, N-terminal pro-B-type natriuretic peptide levels $250 pg/
mL, fibrinogen levels .500 mg/dL and $501 monocytes/mm3 compared with group A patients (p,0.05).
Nevertheless, multivariate logistic regression analysis demonstrated that the independent predictors of
angiographic coronary atherosclerosis were an N-terminal pro-B-type natriuretic peptide level $250 pg/mL,
diabetes mellitus and increased monocyte numbers and fibrinogen plasma concentration, regardless of the
creatinine level or the presence of systolic dysfunction.
CONCLUSIONS: An N-terminal pro-B-type natriuretic peptide plasma concentration of $250 pg/mL is an
independent predictor of angiographic coronary atherosclerosis.
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& INTRODUCTION
Atherosclerosis is a chronic inflammatory disease that
occurs in individuals with low activity levels. It typically
involves endothelial dysfunction and immune mechanisms
that interact with metabolic changes to trigger, propagate
and activate lesions in the arterial tree (1).
The pathogenesis of atherosclerosis includes multifactor-
ial risk factors, such as gender, age, smoking, hypertension,
diabetes mellitus, hypercholesterolemia and first-degree
relatives with a history of atherosclerotic cardiovascular
disease (2). Additionally, monocytes are important cells in
the progression of the disease, and increases in serum acute-
phase proteins reflect low-grade vascular inflammation.
Among other factors, increases in fibrinogen and C-reactive
protein are considered risk factors and have been correlated
with disease severity (3).
Coronary angiography, although invasive, is the first-
choice method for detecting atherosclerosis (4). However,
its use is only indicated when clinical and biochemical
factors are clearly indicative of the presence of athero-
sclerosis (4). Nevertheless, some patients who undergo
coronary angiography do not exhibit atherosclerotic
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diseases. Therefore, new markers for coronary lesions are
required.
B-type natriuretic peptide (BNP) and the N-terminal
fragment of pro-B-type natriuretic peptide (NT-proBNP)
are sensitive indicators of left ventricular dysfunction (5). It
has also been reported that the serum concentrations of
these markers are increased during myocardial ischemia
due to coronary atherosclerosis in patients with normal
ventricular function (5). However, NT-ProBNP is not yet
routinely used as a biomarker for atherosclerosis that
effectively correlates with angiographic identification of
this disease.
This study therefore aimed to investigate the correlation
between atherosclerotic disease and the plasma concentra-
tions of NT-proBNP, hsCRP and fibrinogen, as well as blood
leukocyte and monocyte counts and traditional risk factors
for atherosclerosis, in patients undergoing coronary athero-
sclerosis (CAD) angiography.
& MATERIALS AND METHODS
A) Study Characterization
This was an observational study that included a series of
153 patients admitted to Hospital Universita´rio Walter
Cantı´dio of the Federal University of Ceara´ (HUWC-UFC),
Brazil, between August 2007 and March 2008. The inclu-
sion criteria were a diagnostic hypothesis of stable angina,
unstable angina or acute myocardial infarction and elective
coronary angiography.
The exclusion criteria included the following: previous
percutaneous or surgical myocardial revascularization;
acute or chronic renal dialysis; cancer; infectious or
inflammatory diseases; pulmonary, hepatic, hematological
or valvular heart diseases; congenital heart disease; and
cardiomyopathy.
The study was approved by the Ethics in Research
Committee of HUWC-UFC (protocol number 030.06.01)
and complied with the Helsinki Declaration (1983). All
patients signed an informed consent form.
B) Clinical and Demographic Variables
The demographic and clinical data, including gender, age,
body mass index (BMI), abdominal circumference, meta-
bolic syndrome, smoking, diabetes, hypertension, positive
family history of early-onset atherosclerosis, statin use
and clinical presentation, were collected by interview and
physical examination. A BMI $30 kg/m2 was indicative of
obesity. Abdominal circumference was considered normal
when it was ,80 cm in women and ,94 cm in men.
Metabolic syndrome was defined as the presence of three
or more of the following clinical parameters: abnormal
abdominal circumference, triglycerides $150 mg/dL, high-
density lipoprotein (HDL) cholesterol levels ,40 mg/dL
in men and ,50 mg/dL in women, blood pressure
$130685 mmHg and fasting glucose .100 mg/dL (6).
Patients a pipe, a cigar or five or more cigarettes per day
for at least six months or who had stopped smoking no
more than six months before the start of the study were
considered smokers.
Diabetes mellitus and hypertension were recognized
based on the most recent definitions (7,8).
A positive family history of early-onset atherosclerosis
was based on one of the following findings in first-degree
male relatives before the age of 55 years or in female
relatives before the age of 65 years: atherosclerotic cere-
brovascular disease, peripheral atheromatous arteriopathy,
ischemic heart disease, angina pectoris, myocardial infarc-
tion or sudden ischemic death (2).
Statin users were patients who reported using statins
regularly for at least one month. Patients with stable
angina, unstable angina or acute myocardial infarction were
diagnosed based on clinical criteria and electrocardio-
graphic and biochemical parameters as reported in the
current literature (9).
C) Laboratory Variables
The resting electrocardiogram was considered abnormal
when cardiac arrhythmia, conduction disorders, cardiac
chamber overload, electrically inactive areas and disper-
sion of ventricular repolarization were observable (10).
Cardiomegaly and/or pulmonary venous congestion were
diagnosed by chest radiography (11).
The systolic function of the left ventricle was assessed by
echocardiography based on the measurement of the ejection
fraction and fractional shortening, which were considered
normal when they were .55% and 28%, respectively (12).
After a twelve-hour fasting period, peripheral venous
blood was collected for the following biochemical analyses,
with their corresponding normal values shown in parenth-
eses: glucose (70-99 mg/dL), total cholesterol (up to 200 mg/
dL), triglycerides (,150 mg/dL), uric acid (,7.0 mg/dL in
men and ,5.7 mg/dL in women), urea (up to 24 mg/dL),
creatinine (#0.6 mg/dL), HDL cholesterol (HDL-C) (35-
55 mg/dL in men and 45-65 mg/dL in women), fibrinogen
(180-350 mg/dL) and creatinine kinase-MB fraction (CK-MB)
(7-25 U/L). Total leukocyte and monocyte counts were
considered normal at 4000-10,000/mm3 and 80-1000/mm3,
respectively. Urinalysis was also performed.
The low-density lipoprotein cholesterol (LDL-C) value
was determined from the Friedewald equation. The evalua-
tion was considered unreasonable when triglycerides were
.400 mg/dL (13). Cardiac troponin I was normal if it
was ,0.10 mg/L, but acute myocardial infarction was
considered to be indicated by a value $0.16 mg/L (9).
High-sensitivity C-reactive protein, measured with a turbi-
dimetric immunoassay, was considered normal when it was
#1.0 mg/L (14). Plasma levels of NT-proBNP were mea-
sured using an electrochemiluminescence immunoassay
with a Roche Elecsys 2010 machine (Roche Diagnostics/
Hoffmann-La Roche, Bohemia, NY, USA), with a detection
limit ranging from 5.0-35000.00 pg/mL. The upper limit of
normal was ,125 pg/mL, and the intra- and inter-assay
coefficients of variation were 1.1% and 4.1%, respectively
(15).
D) Cardiac Catheterization and Coronary
Angiography
Cardiac catheterization and coronary angiography were
performed using the technique of Sones or Judkins with
cineangiographic recordings (16). The epicardial coronary
arteries were considered positive for angiographic CAD
when they were completely occluded or had any degree
of partial occlusion. Partial occlusion was defined as a
reduction of the coronary vascular lumen compared with
the nearest normal segment. Coronary angiography was
analyzed by a hemodynamicist and the first author of this
study, and both exhibited consistent interpretations regard-
ing the presence or absence of angiographic CAD.
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Statistical Analysis
Statistical analyses were performed using SPSS 13.0R.
Categorical and continuous variables are presented as
absolute numbers and percentages or as the mean or
median, as appropriate. Fisher’s exact test and the chi-
square test were used to analyze categorical variables. For
quantitative variables with and without normal distribu-
tions, we used Student’s t-test and the Mann-Whitney U
test, respectively. P values ,0.05 were considered to be
significant. The odds ratio was estimated with a confidence
interval of 95%. Multivariate logistic regression was
performed to define factors that were significantly asso-
ciated with the presence of angiographic CAD. The
sensitivity, specificity and accuracy of the model employed
were also determined (17). Sample size estimation was
performed according to previously published methods (18).
The suggested sample size for our study was 74 patients
based on the formula N = [(r + 1).(Za/2 + Z1-b)2]s2]/r.d2,
where Za/2 (1.96 for a 5% level of significance) and Z1-b (0.84
at 80% power) are normal deviates for type I error
(significance level) and study power, respectively. r = n1/
n2 is the sample size ratio required for the two groups
(n1 = 42 patients with a normal coronary artery and n2 = 111
patients with angiographic coronary atherosclerosis), yield-
ing an ‘‘r’’ of 0.38. s and d are, respectively, the pooled
standard deviation and difference in the means of the two
groups (data derived from Table 5). Considering the
markers used in our study, we decided to use C-reactive
protein (CRP) as a reference for the sample size calculation
because it is the most extensively studied biomarker of
inflammation in cardiovascular diseases.
& RESULTS
Table 1 shows the clinical and demographic character-
istics and the main laboratory results of all 153 patients. The
distributions of these parameters were similar between
genders. Patient age ranged from 32-86 years (mean = 62.5
years; median = 62.0 years), with no significant difference
between men and women (p= 0.065) (Table 1).
The sample was divided into two groups according to
coronary angiography results: Group A, patients with
angiographically normal coronary arteries (n = 42; 27.5%);
and Group B, patients with angiographic CAD (n = 111;
72.5%). Angiography demonstrated that all patients with
CAD had one or more fully obstructed coronary arteries or
at least 50% luminal occlusion.
Table 2 shows that all patients diagnosed with acute
myocardial infarction and nearly all diagnosed with instable
angina had angiographic CAD. Stable angina was present in
62.7% of the overall sample, but 97.6% of the group with
angiographically normal coronary arteries were diagnosed
with stable angina.
The associations between normal coronary arteries or
angiographic CAD and the various demographic, clinical
and laboratory data were evaluated in both groups and are
shown in Table 3.
Table 4 presents the odds ratios for categorical variables
that were significantly associated with the presence of
angiographic CAD (p,0.05). Among all the variables,
diabetes mellitus, systolic dysfunction on echocardiogra-
phy, NT-proBNP levels $250 pg/mL, fibrinogen levels
.500 mg/dL, statin use and a monocyte count .501/mm3
were associated with the presence of angiographic CAD.
BMI $30 kg/m2 and increased abdominal circumference
were more prevalent in patients with angiographically
normal coronary arteries. Additionally, the comparisons
between groups A and B, with respect to the quantitatively
expressed variables, are presented in Table 5.
Diabetes mellitus, systolic dysfunction and a NT-proBNP
level $250 pg/mL were analyzed using multivariate logistic
regression because they were strongly associated with the
presence of angiographic CAD (OR $4.9) in the univariate
analyses. Quantitatively, the absolute number of monocytes
per mm3 and fibrinogen and creatinine levels in mg/dL were
included because they were also significantly associated
with angiographic CAD in the univariate analyses (p,0.05).
The statistical analysis yielded results consistent with the
observed clinical correlations, and elevations in fibrinogen,
Table 1 - Descriptive analysis of the sample group.
Clinical and demographic characteristics
Men 78.0 (51.0)*
Women 75.0 (49.0)*
Age 62.5 (11.1)**
Smoker 22.0 (14.4)*
Ex-smoker 69.0 (45.1)*
Non-smoker 62.0 (40.5)*
Diabetes mellitus 55.0 (35.9)*
Hypertension 126.0 (82.4)*
Family history of early-onset atherosclerosis 39.0 (25.5)*
BMI $30 kg/m2 48.0 (31.4)*
Increased abdominal circumference 107.0 (69.9)*
Metabolic syndrome 118.0 (77.1)*
Statin users 80.0 (52.3)*
Laboratory data
Total leukocytes .7500/mm 73 (47.7)1
Monocytes .500/mm 69 (45.1)1
Fibrinogen .350 mg/dL 119 (79.3)2
hsCRP .1 mg/L 125 (82.8)3
Low HDL-C 105 (68.6)4
Total cholesterol/HDL-C ratio ,5 63 (41.2)4
LDL-C/HDL-C ratio ,3.5 84 (56.7)1
Non-HDL-C .160 mg/dL 57 (37.3)4
NT-proBNP $125 pg/mL 87 (59.8)5
Abnormal ECG 115 (75.2)4
Abnormal chest radiography 32 (21.9)6
Systolic dysfunction on echocardiography 25 (19.7)7
*Number of patients (percentage); **mean (standard deviation); Index
number represents the total number of patients for whom laboratory
data were analyzed: 1148 patients, 2150 patients, 3151 patients, 4153
patients, 5145 patients, 6146 patients and 7127 patients. BMI - body mass
index; hsCRP - high-sensitivity C-reactive protein;
ECG - electrocardiogram.
Table 2 - Association between symptoms and the
presence or absence of angiographic coronary
atherosclerosis.
Coronary Artery
Normal Angiographic CAD Total
Clinical
condition Patients % Patients % N %
SA 41 97.6 55 49.5 96 62.7
UA 1 2.4 40 36.0 41 26.8
AMI 2 2 16 14.4 16 10.5
Total 42 100.0 111 100.0 153 100.0
SA - Stable angina; US - Unstable angina; AMI - Acute myocardial
infarction.
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NT-proBNP and monocytes were associated with angio-
graphic CAD, regardless of whether categorical or quantita-
tive variables were considered (Tables 3 and 5).
The variables chosen for inclusion in the multivariate
analysis were those that were assessed in the univariate
analyses and that were also significantly associated with
angiographic CAD. These variables included the following:
diabetes mellitus, BMI, increased abdominal circumference,
systolic dysfunction on echocardiography, NT-proBNP
levels $250 pg/mL, fibrinogen levels .500 mg/dL, creati-
nine, statin use and a monocyte count .501/mm3. As
shown in Table 6, an NT-proBNP level $250 pg/mL, the
presence of diabetes, an increased fibrinogen concentration
and an increased monocyte count were the only variables
significantly associated with the presence of angiographic
CAD in the multivariate analysis. Thus, patients with an
NT-proBNP level $250 pg/mL had an 11.21-fold increased
risk of angiographic CAD. The same result was also
observed in patients with diabetes (8.45-fold increase)
and patients with a one-unit increase in the number of
circulating monocytes (regression coefficient= 0.006) or a
1 mg/dL increase in the plasma fibrinogen concentration
(regression coefficient= 0.007).
Patients with NT-proBNP levels greater than twice the
upper limit of normal ($250 pg/mL) had an odds ratio of
4.94 (confidence interval [CI]: 95% [1.91-12.76]) for angio-
graphic CAD compared with individuals with a lower NT-
ProBNP level (Table 4). Furthermore, the association of this
increase in NT-proBNP with angiographic CAD persisted in
the multivariate analysis, with an odds ratio of 12.21 (CI:
95% [2.49-59.96]) and was superior even to the association of
diabetes mellitus with angiographic CAD in a statistical
model that included creatinine and systolic dysfunction
(Table 6).
In this study, in which 72% of patients exhibited coronary
artery occlusion (111 of 153 patients), the model indicated
an accuracy of 79.7%, a sensitivity of 80.4% and a specificity
of 76.9% for the diagnosis of angiographic CAD, considering
adjustments for prevalence.
Table 3 - Comparison of Groups A and B with respect to categorical variables.
Coronary Artery
Factor Normal
Angiographic coronary
atherosclerosis p-value
Men* 16 (38.1) 62 (55.9) 0.069
Women* 26 (61.9) 49 (44.1) ---
Smokers/Ex-smokers* 23 (54.8) 68 (61.3) 0.605
Non-smokers * 19 (45.2) 43 (38.7) ---
Diabetes mellitus* 9 (21.4) 46 (41.4) 0.024
BMI $30* 21 (50) 27 (24.3) 0.003
Increased abdominal circumference * 35 (83.3) 72 (64.9) 0.030
Statin users * 3 (7.1) 77 (69.4) ,0.001
Family history of early-onset atherosclerosis * 13 (31) 26 (23.4) 0.406
Hypertension* 37 (88.1) 89 (80.2) 0.343
hsCRP .1 mg/L2* (151 p) 36 (87.8) 89 (80.9) 0.111
Total leukocytes .7500/mm3* 15 (35.7) 58 (52.3) 0.064
Fibrinogen .350 mg/dL * (150 p) 7 (17.1) 42 (38.5) 0.019
NT-proBNP $125 pg/mL * (145 p) 7 (17.9) 49 (46.2) 0.002
Monocytes .500/mm3* 11 (26.2) 58 (52.2) 0.010
Metabolic syndrome * 36 (85.7) 82 (73.9) 0.136
Non-HDL-cholesterol .160 mg/dL * 17 (40.5) 40 (36.0) 0.686
Low HDL cholesterol * 30 (71.4) 75 (67.6) 0.865
Total cholesterol/HDL-C ratio ,5* 16 (38.1) 47 (42.3) 0.714
LDL-C/HDL-C ratio ,3.5* (148 p) 21 (52.5) 63 (58.3) 0.577
Systolic dysfunction on echocardiography * (127 p) 1 (3.4) 24 (24.5) 0.015
Abnormal chest radiography * (146 p) 7 (17.9) 25 (23.4) 0.652
Abnormal ECG * 29 (69.0) 86 (77.5) 0.299
*Absolute number (and percentage) of patients; hsCRP - High-sensitivity C-reactive protein; ECG - Electrocardiogram.
Table 4 - Odds ratios for categorical variables significantly
associated with the presence of angiographic coronary
atherosclerosis.
95% Confidence interval
Factor OR LL* UL**
Diabetes Mellitus
No 1.000 2 2
Yes 29.441 8.505 101.912
BMI kg/m2
BMI ,30 1.000 2 2
BMI $30 0.321 0.153 0.677
Abdominal circumference
Normal 1.000 2 2
Increased 0.369 0.150 0.908
Statin use
No 1.000 2 2
Yes 2.595 1.134 5.940
Fibrinogen mg/dL
#350 1.000 2 2
351-500 1.685 0.701 4.053
.500 4.333 1.483 12.658
NT-proBNP pg/mL
,125 1.000 2 2
125#NT-proBNP,250 2.029 0.778 5.296
$250 4.941 1.913 12.761
Monocytes cells/mm3
#500 1.000 2 2
501-750 2.574 1.137 5.827
$751 8.189 1.027 65.323
Systolic dysfunction
No 1.000 2 2
Yes 9.081 1.172 70.337
*Lower limit, ** Upper limit; BMI - Body mass index.
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& DISCUSSION
This study was conducted in patients commonly admitted
to hospital wards, which explains why the majority of
patients presented with stable angina rather than unstable
angina or acute myocardial infarction. The indication for
coronary angiography reveals the need to identify or
exclude the presence of angiographic CAD.
The findings of angiographic CAD in 111 patients and
normal coronary angiography in 42 patients were similar to
those in previous reports in the literature that describe
individuals with clinical signs of angina pectoris who
underwent coronary angiography (19).
Diabetes mellitus was observed in more than one-third
of patients and was more frequent in the group with
angiographic CAD than the group with angiographically
normal arteries. These results are consistent with the
literature (2).
Abdominal and total obesity were more frequent in
group A than in group B. Conceivably, the presence of both
obesity and metabolic syndrome biased the clinical suspi-
cion of angina pectoris and the indication of coronary
angiography in our patients, which may help explain our
findings.
Hypertension was the most prevalent risk factor among
those identified in this study, but its presence did not differ
between groups A and B. Although hypertension favors the
occurrence of atherosclerosis (2) due to its contribution to
left ventricular hypertrophy, the increase in oxygen con-
sumption, the generation of endothelial dysfunction and the
reduction in coronary flow reserve, it can lead to angina
pectoris even in patients with normal coronary artery
angiography (20).
In this study, the total leukocyte count was significantly
higher in the group with angiographic CAD compared with
the group with normal coronary arteries, which may
indicate the important role of this factor in the underlying
inflammatory condition of atherosclerotic disease. Nasir
et al. reported that among the leukocytes, monocytes
are most significantly and independently associated with
peripheral artery disease in the presence of a reduced ankle-
brachial blood pressure index (21). Increases in monocytes
are also strongly correlated with CAD even after adjusting
for smoking and other risk factors (22). Our findings are
consistent with the literature because increased monocyte
counts showed an odds ratio of 2.57 for angiographic
CAD patients compared with those with normal coronary
arteries.
Table 6 - Multivariate logistic regression analysis of angiographic coronary atherosclerosis - estimation of odds ratios in
the presence of diabetes mellitus, N-terminal fragment of pro-B-type natriuretic peptide level .250 pg/mL, increased
fibrinogen concentration and increased monocyte count.
95% CI*
Factor Regression Coefficient SE p-value OR LL** UL***
Fibrinogen 0.007 0.003 0.048 1.007 1.001 1.013
Monocytes 0.006 0.002 0.002 1.006 1.002 1.010
NT-proBNP $250 pg/mL 2.503 0.812 0.002 12.219 2.490 59.963
Diabetes mellitus 2.246 0.807 0.005 9.453 1.944 45.969
Constant -5.791 1.828 0.002 0.003 2 2
*Confidence interval; ** LL-Lower Limit, UL-Upper Limit ***
Table 5 - Comparison of Groups A and B with respect to quantitative variables.
Coronary Artery
Factor Normal Angiographic CAD p-value
Age* (years) 60.23 (9.52) 63.38 (11.58) 0.090
BMI* 30.20 (4.07) 27.73 (4.48) 0.002
Abdominal circumference.* - cm 97.92 (10.84) 95.05 (9.17) 0.102
hsCRP* - mg/L (151 p) 0.26 (0.20) 0.88 (2.92) 0.386
Total leukocytes/mm3* 6859.5 (1941.1) 7662.9 (2126.2) 0.034
Fibrinogen * - mg/dL (150 p) 401.5 (80.6) 474.8 (127.3) 0.002
NT-proBNP - pg/mL* (145 p) 435.8 (1375.7) 719.3 (1272.5) 0.001
Monocytes/mm3* 413.9 (140.2) 545.2 (206.5) ,0.001
Non-HDL cholesterol - mg/dL* 150.8 (40.1) 147.0 (43.1) 0.620
HDL cholesterol* - mg/dL 34.9 (10.4) 35.7 (12.5) 0.548
Total cholesterol * - mg/dL 185.8 (43.0) 182.6 (45.7) 0.697
LDL cholesterol* - mg/dL (148 p) 117.4 (39.1) 112.4 (37.9) 0.489
VLDL cholesterol* - mg/dL (148 p) 34.1 (15.3) 32.3 (13.5) 0.481
Triglycerides* - mg/dL 188.6 (112.2) 172.7 (100.2) 0.430
Uric acid* - mg/dL 5.51 (1.4) 5.5 (1.3) 0.987
Urea* - mg/dL 35.1 (6.4) 40.0 (19.2) 0.997
Creatinine* - mg/dL 0.79 (0.22) 0.93(0.40) 0.031
EFLV - % - (127 p) 61.1 (8.58) 57.2 (11.27) 0.260
LV - DD % - (127 p) 33.1 (6.46) 31.1 (7.07) 0.441
*mean (standard deviation); hsCRP: High-sensitivity C-reactive protein; EFLV: Ejection fraction of the left ventricle; LV: Left ventricle; DD: Systolic
shortening fraction.
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A meta-analysis involving 154,211 healthy individuals
demonstrated an association between increased fibrinogen
and the incidence of CAD, even after adjusting for common
risk factors and high-sensitivity C-reactive protein (23).
Levenson et al. found that the presence and extent of
asymptomatic atherosclerosis in the carotid and femoral
arteries and in the abdominal aorta were independently
related to the plasma fibrinogen level of a never-treated
male population with increased cardiovascular risk (24).
However, it is debatable whether plasma fibrinogen is
a causative factor of or merely a marker for CAD
(25,26). Regardless of whether it is a marker or mediator
of atherosclerosis, we demonstrated that patients in the
present study with higher plasma levels of fibrinogen had
an odds ratio of 4.33 for angiographic CAD compared with
those with normal coronary arteries.
Epidemiological evidence shows that C-reactive protein,
when considered alone, is even suggested to be a marker of
atherosclerosis, exhibiting a higher value than that of LDL-C
(2). In our study, the level of C-reactive protein could have
been underestimated. In the angiographic CAD group,
most of the patients took simvastatin; in just 14 days,
this medication can reduce the plasma concentration of C-
reactive protein by up to 25%, regardless of its effect on
LDL-C (27) and therefore likely contributed to the similar
findings regarding dyslipidemia in the two groups.
In clinical practice, asymptomatic patients and patients
with chest pain who have significant risk factors for
atherosclerosis are commonly diagnosed with CAD.
Therefore, a noninvasive method of examination that could
identify individuals most likely to be diagnosed with CAD
would be useful prior to submitting them to coronary
angiography. With this consideration, chest radiography is
limited to the exclusion of other causes of chest pain (11). In
the present study, chest radiography was only abnormal in
22.0% of subjects and did not differ between groups A and B.
Additionally, electrocardiogram was also ineffective (10)
and was abnormal in 75.0% of our patients, with no
difference between patients with normal arteries or CAD.
Moreover, systolic dysfunction assessed by echocardio-
graphy is also inappropriate for the diagnosis of CAD (12).
As a categorical variable, systolic dysfunction was signifi-
cantly more common in group B than in group A, but it was
observed in only 20.0% of the entire patient population and
was not indicative of CAD, regardless of whether it was
analyzed as a quantitative variable or in the multivariate
analysis.
However, the increase in plasma NT-proBNP, found in
60.0% of patients, was much more frequent than systolic
dysfunction. Indeed, NT-proBNP was higher in patients
with angiographic CAD than in group A, suggesting the
utility of this biochemical marker as a non-invasive method
for the identification of CAD (28).
These findings are consistent with the literature; increased
BNP and NT-proBNP levels have been shown to be related
to the severity of coronary atherosclerosis and ischemic
myocardial impairment independent of ventricular function
(29). Therefore, even in the absence of left ventricular
dysfunction, myocardial ischemia has been shown to
augment cardiac BNP gene expression and increase plasma
BNP and proBNP concentrations. Thus, elevated BNP and
proBNP concentrations do not necessarily reflect heart
failure but may result from cardiac ischemia (30).
According to Wolber et al., who measured NT-proBNP
levels in 781 consecutive patients with normal left
ventricular function referred for coronary angiography
due to symptoms or signs of CAD, this peptide may be a
marker of non-obstructive CAD and significant coronary
stenosis (28).
As acute myocardial infarction and sudden cardiac
death are occasionally the first manifestations of CAD, the
concentrations of these peptides may help identify patients
with myocardial ischemia who are not diagnosed through
routine exams. They may also help stratify the risk of acute
cardiovascular events, similar to their use in the stratifica-
tion of patients with diabetes or those recovering from
stroke (31). However, NT-proBNP and BNP levels are also
increased during kidney failure, ventricular hypertrophy,
diastolic dysfunction, atrial fibrillation, valvular heart
disease, cardiotoxicity, sepsis, hyperthyroidism, liver cir-
rhosis, pulmonary embolism and even right heart failure
secondary to chronic lung disease (32).
In the present study, NT-proBNP levels were increased to
more than twice the upper limit of normal. In addition,
rigorous clinical and laboratory analyses attenuated con-
founding factors. In our opinion, the significant correlation
found between elevated NT-proBNP levels and angio-
graphic CAD most likely resulted from the pooled analysis
of patients with stable angina or acute coronary syndrome
because the elevation of this peptide is much higher in
the latter condition (29). Notably, the correlation between
increased NT-proBNP and the presence of angiographic
CAD was also consistent with the release of BNP by
coronary atheromatous plaques (33).
In the present study, the correlation between chronic
nephropathy and angiographic CAD, although significant
(p= 0.031) the quantitative analysis, detected by the
increased creatinine in group B was not verified in the
multivariate model, perhaps because patients with renal
failure requiring dialysis were excluded from our study.
It is important to mention the lack of correlation of
angiographic CAD with smoking, a positive family history
of early atherosclerosis, hypertension, increased high-
sensitivity C-reactive protein, metabolic syndrome, abnor-
mal cholesterol and obesity. However, as previously
discussed, several of these factors cause or are correlated
with angina pectoris in angiographically normal coronary
arteries (19,20,34).
Two previous studies investigated the correlation
between NT-proBNP and CAD (35,36). Ndrepepa et al.
showed in a large series of consecutive patients who had
stable angina, unstable angina and acute myocardial
infarction that plasma NT-proBNP concentrations increased
progressively with the increase in CAD severity (35). They
also demonstrated that individuals who had acute coronary
syndromes (unstable angina and acute myocardial infarc-
tion) showed a weaker correlation between plasma concen-
trations of NT-proBNP and left ventricular ejection fraction
compared with patients who had stable angina (35). The
authors concluded that NT-proBNP concentrations are high
across the entire spectrum of CAD and parallel the clinical
or angiographic severity of CAD. (35). In addition, Sakai
et al. suggested that the transcardiac increase in NT-proBNP
from the heart increases with the severity of coronary artery
stenosis, independent of hemodynamic overload and that
plasma NT-proBNP may be superior to BNP for assessing
disease severity in CAD patients (36). Our investigation
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followed the same rationale as that described in those
two studies (35,36). However, it is worth noting that
the population studied by Ndrepepa, namely, European
individuals, and the patients evaluated by Sakai, namely,
Japanese individuals, are genetically much more homoge-
neous than the individuals included in our study, which was
primarily composed of multiracial individuals. Despite this
difference, we reached similar conclusions. As reviewed by
Albert, elevations in markers of inflammation and thrombo-
sis, such as high-sensitivity C-reactive protein and fibrino-
gen, are also associated with increased cardiovascular
disease risk, and few data are available across racial/ethnic
groups given that most of the studies were performed
in Caucasian populations (37). Thus, our study, together
with several other studies, adds support for the use of NT-
proBNP in the clinical setting as one possible marker of CAD.
In our study, the association between NT-proBNP and
CAD did not establish causality. We also note that the main
limitation of our study is the small number of patients
included. The small sample size used, compared with other
studies (28), can be partially explained by the fact that our
study was performed at only one institution, as well as by
the exclusion criteria adopted. Despite these limitations,
we were able to identify a statistically significant clinical
correlation between plasma levels of NT-proBNP and
coronary atherosclerosis.
Therefore, in this study, we showed that plasma NT-
proBNP, diabetes mellitus, circulating monocytes and
fibrinogen were positively correlated with angiographic
CAD. The association of these variables in a model adjusted
for the presence of systolic dysfunction and plasma crea-
tinine had a sensitivity of 80.4%, specificity of 76.9% and
diagnostic accuracy of 79.7% for the diagnosis of angio-
graphic CAD.
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